Join our daily newsletter At The Bell to receive exclusive market insights
- OncoSil Medical (OSL) has received regulatory approval for its OncoSil device in Switzerland
- This means the company is now able to market and sell its OncoSil device in Switzerland in addition to the U.K. and European Union
- The namesake device implants a pre-determined dose of beta radiation directly into the cancerous tissue via ultrasound guidance while chemotherapy is used to destroy it
- The device has received regulatory clearances in Malaysia, Singapore and New Zealand
- OncoSil is up 6.67 per cent on the market and shares currently trading for 16 cents each
OncoSil Medical (OSL) has received regulatory approval for its OncoSil device in Switzerland.
This means the company is now able to market and sell its OncoSil device in Switzerland in addition to the U.K. and European Union.
The company’s namesake device is designed to treat patients with advanced and unremovable pancreatic cancer and is used in tandem with chemotherapy.
It is a brachytherapy (cancer treatment) device that implants a pre-determined dose of beta radiation directly into the cancerous tissue via endoscopic ultrasound guidance.
The ultrasound then uses high-frequency sound waves to produce detailed images of the lining and walls of specific organs, with the beta particles travelling a short distance to the tissue that is causing the damage.
This helps locate the cancerous cells and chemotherapy is then used to destroy them.
Current treatments include surgery, chemotherapy, radiation, or chemoradiation therapy, however, these cause nausea, fatigue, hair loss, and digestive and skin problems.
OncoSil has also received regulatory clearances in Malaysia, Singapore and New Zealand.
Company shares are up 6.67 per cent and are trading for 16 cents each at 1:49 pm AEDT.
